Follettie M T, Ellis D K, Donaldson D D, Hill A A, Diesl V, DeClercq C, Sypek J P, Dorner A J, Wills-Karp M
Department of Molecular Profiling and Biomarker Discovery, Cambridge, MA 02140, USA.
Pharmacogenomics J. 2006 Mar-Apr;6(2):141-52. doi: 10.1038/sj.tpj.6500357.
Accumulating evidence in animal models and human asthma support a central role for IL-13 signaling in disease pathogenesis. In order to identify asthma and therapy associated genes, global transcriptional changes were monitored in mouse lung following antigen challenge (ovalbumin (OVA)), either alone or in the presence of a soluble IL-13 antagonist. Changes in whole lung gene expression after instillation of mIL-13 were also measured both in wild type and STAT6 deficient mice. A striking overlap in the gene expression profiles induced by either OVA challenge or mIL-13 was observed, further strengthening the relationship of IL-13 signaling to asthma. Consistent with results from functional studies, a subset of the OVA-induced gene expression was significantly inhibited by a soluble IL-13 antagonist while IL-13-modulated gene expression was completely attenuated in the absence of STAT6-mediated signaling. Results from these experiments greatly expand our understanding of asthma and provide novel molecular targets for therapy and potential biomarkers of IL-13 antagonism.
动物模型和人类哮喘中越来越多的证据支持白细胞介素-13信号通路在疾病发病机制中起核心作用。为了识别与哮喘和治疗相关的基因,在小鼠肺部抗原激发(卵清蛋白(OVA))后,单独或在可溶性白细胞介素-13拮抗剂存在的情况下,监测了整体转录变化。还在野生型和STAT6缺陷型小鼠中测量了滴注mIL-13后全肺基因表达的变化。观察到OVA激发或mIL-13诱导的基因表达谱有显著重叠,进一步加强了白细胞介素-13信号通路与哮喘的关系。与功能研究结果一致,OVA诱导的基因表达的一个子集被可溶性白细胞介素-13拮抗剂显著抑制,而在没有STAT6介导的信号传导的情况下,白细胞介素-13调节的基因表达完全减弱。这些实验结果极大地扩展了我们对哮喘的理解,并为治疗提供了新的分子靶点以及白细胞介素-13拮抗作用的潜在生物标志物。